P3 Health Partners (NASDAQ:PIII – Get Rating) and Sema4 (NASDAQ:SMFR – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.
This is a summary of current ratings and price targets for P3 Health Partners and Sema4, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|P3 Health Partners||0||0||1||0||3.00|
Sema4 has a consensus target price of $3.70, suggesting a potential upside of 262.75%. Given Sema4’s higher possible upside, analysts clearly believe Sema4 is more favorable than P3 Health Partners.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|P3 Health Partners||N/A||N/A||N/A||N/A||N/A|
|Sema4||$212.20 million||1.81||-$245.39 million||($0.58)||-1.76|
P3 Health Partners has higher earnings, but lower revenue than Sema4.
This table compares P3 Health Partners and Sema4’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|P3 Health Partners||N/A||N/A||N/A|
Volatility and Risk
P3 Health Partners has a beta of 1.97, indicating that its stock price is 97% more volatile than the S&P 500. Comparatively, Sema4 has a beta of 2.08, indicating that its stock price is 108% more volatile than the S&P 500.
About P3 Health Partners
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. The company is based in Henderson, Nevada.
Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.
Receive News & Ratings for P3 Health Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for P3 Health Partners and related companies with MarketBeat.com's FREE daily email newsletter.